Association of anticoagulant choice with death in the primary treatment of noncancer venous thromboembolism: Medicare 2011-2018

1

The study analyzed 6-month all-cause mortality in Medicare beneficiaries with noncancer venous thromboembolism treated with different anticoagulants.
2

Rivaroxaban was associated with lower mortality rates compared to warfarin, with a hazard ratio of 0.82.
3

No significant mortality difference was found between apixaban and warfarin, with a hazard ratio of 0.96.
4

In head-to-head comparisons, apixaban had a higher mortality risk than rivaroxaban, with a hazard ratio of 1.14.
5

The findings suggest that DOACs are safe for patients with VTE and concomitant kidney or liver disease, although residual confounding may exist.

American Journal Of Epidemiology

by Rob F Walker, Neil A Zakai, Richard F Maclehose, Faye L Norby, Alvaro Alonso, Pamela L Lutsey
August 9, 2024

1